Cargando…
Economic evaluation of Cytosponge®-trefoil factor 3 for Barrett esophagus: A cost-utility analysis of randomised controlled trial data
BACKGROUND: Esophageal adenocarcinoma has a very poor prognosis unless detected early. The Cytosponge-trefoil factor 3 (TFF3) is a non-endoscopic test for Barrett esophagus, a precursor of esophageal adenocarcinoma. Randomised controlled trial data from the BEST3 trial has shown that an offer of Cyt...
Autores principales: | Swart, Nicholas, Maroni, Roberta, Muldrew, Beth, Sasieni, Peter, Fitzgerald, Rebecca C., Morris, Stephen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225801/ https://www.ncbi.nlm.nih.gov/pubmed/34195582 http://dx.doi.org/10.1016/j.eclinm.2021.100969 |
Ejemplares similares
-
Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial
por: Fitzgerald, Rebecca C, et al.
Publicado: (2020) -
Barrett’s oESophagus trial 3 (BEST3): study protocol for a randomised controlled trial comparing the Cytosponge-TFF3 test with usual care to facilitate the diagnosis of oesophageal pre-cancer in primary care patients with chronic acid reflux
por: Offman, Judith, et al.
Publicado: (2018) -
Acceptability of the Cytosponge procedure for detecting Barrett's oesophagus: a qualitative study
por: Freeman, Madeleine, et al.
Publicado: (2017) -
Detecting Barrett oesophagus using Cytosponge
por: Hindson, Jordan
Publicado: (2020) -
A88 EVALUATING THE ACCEPTABILITY AND EFFICACY OF CYTOSPONGE FOR BARRETT'S ESOPHAGUS: A SINGLE CENTRE CROSS-SECTIONAL STUDY
por: Alqattan, A E, et al.
Publicado: (2023)